SCHEMBL6548219

SCHEMBL6548219

O=C1c2ccccc2C(=O)c2c1cc(O)c(C(=O)O)c2O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 4/20 0.67
MCL1 Q07820 4/20 0.67
ALDH1A1 P00352 3/20 0.54
MEN1 O00255 3/20 0.54
MAPT P10636 3/20 0.54
MAOA P21397 3/20 0.54
KMT2A Q03164 3/20 0.54
KDM4E B2RXH2 2/20 0.54
CYP3A4 P08684 2/20 0.54
HPGD P15428 2/20 0.54
ALOX15 P16050 2/20 0.54
ALOX12 P18054 2/20 0.54
MAPK1 P28482 2/20 0.54
RECQL P46063 2/20 0.54
DAPK1 P53355 2/20 0.54
CYP1B1 Q16678 2/20 0.54
HSD17B10 Q99714 2/20 0.54
APEX1 P27695 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
PKLR P30613 4/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29407198 1.00 BCL2 (0.67) BCL2MCL1ALDH1A1MEN1MAPT
SCHEMBL3955176 0.87 BCL2 (0.67) BCL2MCL1ALDH1A1MEN1MAPT
SCHEMBL28019688 0.82 MAPT (0.55) BCL2MCL1ALDH1A1MEN1MAPT
SCHEMBL23198952 0.81 MAPT (0.61) BCL2MCL1ALDH1A1MEN1MAPT
SCHEMBL555230 0.80 BCL2 (1.00) BCL2MCL1ALDH1A1MEN1MAPT
SCHEMBL29384381 0.80 BCL2 (1.00) BCL2MCL1ALDH1A1MEN1MAPT
SCHEMBL29388375 0.80 BCL2 (1.00) BCL2MCL1ALDH1A1MEN1MAPT
SCHEMBL23199041 0.80 MAPT (0.60) BCL2MCL1ALDH1A1MEN1MAPT
SCHEMBL5075855 0.79 ALDH1A1 (0.52) BCL2MCL1ALDH1A1MEN1MAPT
SCHEMBL29360530 0.79 ALDH1A1 (0.52) BCL2MCL1ALDH1A1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3943085-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2022-01-26 EP claimed
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH ZURICH (CH) 2021-06-24 US claimed
EP-3801507-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2021-04-14 EP claimed
EP-1381355-A2 MATRIX METALLOPROTEINASE INHIBITORS KIMBERLY-CLARK CORPORATION (US) 2004-01-21 EP claimed
US-6600057-B2 Derivatives of 4,5-dihydroxyanthraquinone-2-carboxylic acid; wound healing agents KIMBERLY-CLARK WORLDWIDE, INC. 2003-07-29 US claimed
WO-2002053146-A2 MATRIX METALLOPROTEINASE INHIBITORS KIMBERLY-CLARK WORLDWIDE, INC. (US) 2002-07-11 WO claimed
US-20020086877-A1 Matrix metalloproteinase inhibitors AVENT, INC. 2002-07-04 US claimed
US-4602913-A Use of hydroxyanthraquinones for the coloration of human keratin fibres L'OREAL (FR) 1986-07-29 US claimed
EP-3943085-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2022-01-26 EP disclosed
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH ZURICH (CH) 2021-06-24 US disclosed
EP-3801507-A2 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION ETH Zurich (CH) 2021-04-14 EP disclosed
EP-0665775-B1 ANTHRAQUINONE INHIBITION OF METHANE PRODUCTION IN METHANOGENIC BACTERIA BIO TECH RESOURCES (US) 1997-09-03 EP disclosed
US-5648258-A CONTROLLING METHANE PRODUCTION FOR BETTER FEED EFFICIENCY IN CATTLE BIO-TECHNICAL RESOURCES (US) 1997-07-15 US disclosed
EP-0665775-A1 ANTHRAQUINONE INHIBITION OF METHANE PRODUCTION IN METHANOGENIC BACTERIA. BIO TECH RESOURCES (US) 1995-08-09 EP disclosed
WO-1994008738-A1 ANTHRAQUINONE INHIBITION OF METHANE PRODUCTION IN METHANOGENIC BACTERIA BIO-TECHNICAL RESOURCES LP (US) 1994-04-28 WO disclosed
EP-0234084-A1 Rubber composition, an article of rubber reinforced with brass plated steel and a method of making such an article GENCORP INC. (US) 1987-09-02 EP disclosed
US-4615369-A POLYHYOROXY ANTHRAQUINONE FOR IMPROVED HUMID AGED ADHESION; TIRES GENCORP (US) 1986-10-07 US disclosed
US-4602913-A Use of hydroxyanthraquinones for the coloration of human keratin fibres L'OREAL (FR) 1986-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086877-A1 Matrix metalloproteinase inhibitors MMP26, MMP13, MMP9 BCL2 1225/4885MCL1 1447/4885ALDH1A1 283/4885
US-20210186947-A1 TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION TOMM70, TOMM34, TIMM50 BCL2 2450/4885MCL1 2381/4885ALDH1A1 3685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.